Shire PLC (SHPG) Coverage Initiated by Analysts at FBR & Co
FBR & Co began coverage on shares of Shire PLC (NASDAQ:SHPG) in a research report sent to investors on Thursday morning. The firm issued a buy rating and a $201.00 target price on the biopharmaceutical company’s stock.
A number of other research firms also recently issued reports on SHPG. BidaskClub raised shares of Shire PLC from a strong sell rating to a sell rating in a report on Friday, June 23rd. ValuEngine raised shares of Shire PLC from a hold rating to a buy rating in a report on Thursday, July 6th. HSBC Holdings plc raised shares of Shire PLC from a reduce rating to a hold rating in a report on Thursday, July 6th. Piper Jaffray Companies set a $159.00 price objective on shares of Shire PLC and gave the stock a hold rating in a report on Wednesday, July 26th. Finally, Cantor Fitzgerald set a $222.00 price objective on shares of Shire PLC and gave the stock a buy rating in a report on Saturday, July 1st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $219.25.
Shares of Shire PLC (SHPG) traded down 1.74% on Thursday, hitting $145.25. The stock had a trading volume of 1,078,686 shares. Shire PLC has a 1-year low of $139.36 and a 1-year high of $192.64. The company has a market capitalization of $43.26 billion, a PE ratio of 64.99 and a beta of 1.63. The firm has a 50-day moving average of $153.97 and a 200 day moving average of $164.18.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. On average, equities analysts anticipate that Shire PLC will post $14.92 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Shire PLC (SHPG) Coverage Initiated by Analysts at FBR & Co” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/shire-plc-shpg-coverage-initiated-by-analysts-at-fbr-co/1644482.html.
The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be paid a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 41.07%.
Several large investors have recently modified their holdings of SHPG. Hartford Financial Management Inc. raised its stake in shares of Shire PLC by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 32 shares during the last quarter. YorkBridge Wealth Partners LLC raised its stake in shares of Shire PLC by 81.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 317 shares during the last quarter. Pacer Advisors Inc. bought a new position in shares of Shire PLC during the second quarter valued at about $171,000. Tower Research Capital LLC TRC raised its stake in shares of Shire PLC by 45.3% during the first quarter. Tower Research Capital LLC TRC now owns 1,122 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 350 shares during the last quarter. Finally, Iberiabank Corp bought a new position in shares of Shire PLC during the second quarter valued at about $203,000. 19.24% of the stock is owned by hedge funds and other institutional investors.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.